newsfilter
← Latest News
Business Wire·

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer